Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $20.40.

Several research analysts have issued reports on TLX shares. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Royal Bank Of Canada downgraded shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday.

Telix Pharmaceuticals Price Performance

Shares of Telix Pharmaceuticals stock opened at $10.46 on Wednesday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $16.94. The business has a 50-day simple moving average of $10.36 and a 200 day simple moving average of $9.07. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Insiders Place Their Bets

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch acquired 34,500 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were purchased at an average cost of $14.48 per share, with a total value of $499,560.00. Following the completion of the purchase, the chief executive officer owned 20,709,500 shares of the company’s stock, valued at approximately $299,873,560. This represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the last quarter. Bank of America Corp DE boosted its stake in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XTX Topco Ltd acquired a new position in Telix Pharmaceuticals during the 4th quarter valued at about $89,000. XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the 1st quarter worth approximately $120,000. Finally, IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.